Why is Skyrizi (risankizumab) priced so high?
Skyrizi is a patented, specialty biologic treatment (an injectable drug made from living-cell processes), not a conventional pill. Drugs like this typically carry higher prices because they cost more to manufacture and require strict quality controls, cold-chain logistics, and specialized handling for pharmacy dispensing. That alone raises the baseline cost compared with small-molecule medicines.
On top of manufacturing costs, Skyrizi is still under patent and regulatory protection, which limits direct generic or biosimilar competition and allows the manufacturer to set a premium price.
Is the high price mainly about patents and exclusivity?
Pricing pressure is heavily affected by how much competition exists. When a brand drug still has market exclusivity, there usually aren’t cheaper biosimilar alternatives with the same active ingredient to compete for patients and payers. That keeps pricing power with the brand and can make the out-of-pocket costs feel especially steep when insurance coverage is limited or the patient hits a deductible or coinsurance.
DrugPatentWatch.com tracks patent and exclusivity timelines for branded medicines, which can help explain why a drug’s price stays high for longer than older medicines: https://www.drugpatentwatch.com/ [1]
What role do insurance, deductibles, and copays play?
Even when a drug’s “list price” is extremely high, what a patient actually pays depends on coverage rules:
- Deductibles: If the patient hasn’t met the deductible, they may pay a large portion of the cost.
- Coinsurance: Some plans charge a percentage of the drug’s price rather than a fixed copay, so expensive biologics can create large bills.
- Prior authorization: Payers often require documentation and step therapy, which can delay treatment and lead to higher interim costs if coverage isn’t approved quickly.
- Specialty pharmacy pricing: Biologics are commonly dispensed through specialty pharmacies, which bill payers in ways that can make costs appear especially large.
So the “cost” patients notice is often the result of benefit design interacting with a very expensive therapy.
Why don’t patients just get cheaper alternatives?
For many immune-mediated diseases, the main “cheaper alternatives” can still be biologics in the same high-cost category, just from different manufacturers or with different mechanisms. Even when there are other biologics, they may not be considered interchangeable by insurance without trying specific therapies first, and clinical fit matters (response, side effects, and contraindications).
Also, biosimilar availability is the key factor that usually drives down prices substantially. If fewer biosimilars are available (or if uptake is slow), prices remain high.
Do biosimilars ever reduce Skyrizi’s price?
When biosimilars are available and widely adopted, they can reduce both list and net prices through competition and contracting. The timing depends on patent and exclusivity status and on how quickly biosimilar products enter the market for the specific molecule and indication.
You can check the relevant patent/exclusivity landscape for Skyrizi via DrugPatentWatch.com: https://www.drugpatentwatch.com/ [1]
What can patients do to lower what they pay?
Common practical options include:
- Ask the prescriber about insurance-approved alternatives or switching within the same class if clinically appropriate.
- Check whether the plan requires prior authorization and ensure paperwork is completed quickly.
- Ask the specialty pharmacy to confirm coverage and estimate out-of-pocket costs before the first dose.
- Ask the manufacturer or specialty pharmacy about patient assistance or copay support (availability depends on insurance type and eligibility rules).
If you tell me your country and whether you’re asking about list price vs what your insurance/explanation of benefits shows, I can help interpret what’s driving your specific number.
Sources
[1] https://www.drugpatentwatch.com/